Editas looks ready to launch on the weekly with a bounce off support and 3x rsi hidden bullish divergence. The full extension of this triangle using the 1.618 gives us 213 dollars as the final take profit.
I dont know whats going on fundamentally with this company, but in terms of the technicals: im in.
This one is a Sleeping giant! There is so much indications to go long on this bad boy. EDIT is a true sleeper but when it moves get ready to hit the gears on full throttle. We are seeing tons of accumulation on the TTM indicator it is only a matter of time before the squeeze goes into play. Earnings are right around the corner and good and clear divergence showing...
I think EDIT could make its move to $100 if it breaks the resistance in its third attempt.
Worth a watch - but not totally confident that it can do it.
This was a breakout trade I had been charting. Looked like and ascending triangle. We got rejection at 73$ came back to backtest the flat previous reisatnce line as support and failed. I was stopped out of my long. With recent upper rejection, we could make a case it’s a rising wedge not an ascending. Triangle, however this 63$ range would be previous support of...
Since breakout we go small rejection at 73$ however this is the biggest moment. This is what breakout trading is about. You wait for a confirmed backtest hold of previous resiatnce as support, you wait for a bounce with some confirmed volume. This is exactly what edit is doing. It can fail the hold yea, however if the backtest holds and we don’t start...
Breaking through resiatnce here I am long at 68.40 we’ll see how this trade goes. Got 39
Shares on this trade. Got 4 hour MACd cross that came in, daily cross should come in soon. Daily rsi is 70 usually peaks around 82. 70$ is always a big resiatnce which seems to be breaking through.
Trying so hard to breakout. We had a potential fake wick through resiatnce earlier today. We def have to watch and see how this plays out. Of course we can look for volume support , closes above 68.70 level, or even a run and fall back down backtest as support and bounce… breakout trades are my favorite however, sometimes can go south quickly as your buying a a...
Been in this for a little while now since the change in market structure and added a few times to this position so not the best avg weighted entry but still well in profit.
Classic sweep of lows and change in market structure has me excited on this position and more recently over the last month with the gap up above the previous short term high and now the...
Will EDIT finally see its day?
What a loser for such a long time. I initially started getting in this for the break of $100/share and just as I was building my position with common shares, it dumped.... for like 8 months.
Looking for $80 / share to exit.
Keeping eyes on this beast this week. Seems to have formed either a bull pennant or symetrical triangle. Strong resiatnce formed at 70$ range. Haven’t been able to close a 4hour candle above 66.30. I’m looking to see if we can break bullish out of this I may make a trade but confirmation. Is needed. I’ll be watching and waiting for my entry with alerts set. ...
EDIT has been a growth name I've been watching for some time, came up right to my price target which I posted a few months back. I'm watching the 61.5 level as a strong resistance level, also the 272 Fib level. I'd like to see a break above to go long with a PT of 65.4, but it looks like a handle will come next as price retreated right from the resistance zone and...
Fantastically sensual chart.
Through up some indicators. Red labels are 3 point confluence. That blue circle indicates a possible 4 point confluence. Let’s see what plays out.
All major gene editing stocks look like they're on the cusp of big moves higher. (See last post on NTLA)
Zoomed in on the shorter time frame we have a trigger off the 618 4hr retrace. There's some overhead supply in the 50s for shorter term targets, but this is a long term play with...
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
NASDAQ
